Patents by Inventor David McGowan
David McGowan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11957683Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 15, 2022Date of Patent: April 16, 2024Assignee: Aligos Therapeutics, Inc.Inventors: Sandrine Vendeville, Pierre Jean-Marie Bernard Raboisson, David McGowan, Yannick Debing
-
Patent number: 11952374Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 19, 2021Date of Patent: April 9, 2024Assignee: Aligos Therapeutics, Inc.Inventors: Sandrine Vendeville, Pierre Jean-Marie Bernard Raboisson, David McGowan
-
Publication number: 20240095645Abstract: A method of generating customizable goal representation is disclosed. A request from a user to view a goal representation is received. A flexible goal ontology is accessed that comprises one or more goal entities, one or more goal relationships between the goal entities, or one or more goal properties, the one or more goal properties including one or more metadata attributes relating to the one or more goal entities. A set of mapping rules is obtained that defines mappings between one or more goals. The set of mapping rules is evaluated to assemble a customized goal representation tailored to the user. The customized goal representation is updated based on a revaluation of the mapping rules affected by changes to the one or more goal entities, the one or more goal relationships, or the one or more properties.Type: ApplicationFiled: September 21, 2023Publication date: March 21, 2024Inventors: Sven Martin Andreas Elfgren, Friedrich I. Riha, Elliot Piersa Dahl, Eric Koslow, Nicole Jensen McMullin, Natasha Hede, Connie Lynn Chen, Alexa Jean Kriebel, Chije Wang'ati, JR., Megan McGowan, Ami Tushar Bhatt, Jeffrey Ryan Gurr, Tyler Kowalewski, Rahul Rangnekar, Byron Sha Yang, Jerry Wu, Ricky Rizal Zein, Romain Beauxis, Adnan Chowdhury, Priya Balasubramanian, Gilles Yvetot, Shaylan Hawthorne, Adnan Pirzada, Matthew Michael Parides, Jenna Nicole Soojin Lee, Ian William Richard, Laura Elizabeth Pearson, Christian Nguyen, Tovin Thomas, Adam Carter, David Achee, David Christopher Sally, Miranda Howitt, Vincent Yao, Seth Goldenberg, Aimee Jin Peng, William Qingdong Yan, Matthew Stephen Wysocki, Michael Ryan Shohoney, Ryan Maas, Asha Camper Singh, Leonardo Faria, Elliot Piersa Dahl
-
Publication number: 20230382909Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 17, 2023Publication date: November 30, 2023Inventors: Sandrine Vendeville, David McGowan, Yannick Debing, Pierre Jean-Marie Bernard Raboisson
-
Publication number: 20230374008Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 18, 2023Publication date: November 23, 2023Inventors: Sandrine Vendeville, David McGowan, Yannick Debing, Pierre Jean-Marie Bernard Raboisson
-
Publication number: 20230051483Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 15, 2022Publication date: February 16, 2023Inventors: Sandrine Vendeville, Pierre Jean-Marie Bernard Raboisson, David McGowan, Yannick Debing
-
Publication number: 20230031213Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.Type: ApplicationFiled: June 15, 2022Publication date: February 2, 2023Inventors: Tongfei Wu, Pierre Jean-Marie Bernard Raboisson, Francois Gonzalvez, Antitsa Dimitrova Stoycheva, Cheng Liu, Jerome Deval, David McGowan
-
Publication number: 20220119385Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 19, 2021Publication date: April 21, 2022Inventors: Sandrine Vendeville, Pierre Jean-Marie Bernard Raboisson, David McGowan
-
Publication number: 20220112194Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 30, 2021Publication date: April 14, 2022Inventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Jerome Deval, Leonid Beigelman, David McGowan, Yannick Debing, Francois Gonzalvez
-
Publication number: 20220048922Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 28, 2021Publication date: February 17, 2022Inventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Jerome Deval, Leonid Beigelman, David McGowan, Yannick Debing
-
Patent number: 11203473Abstract: A cooler device having a body and lid that can be secured shut and locked against the cooler body with a combination lock, keypad lock, key operated lock or electronic lock installed on the body of the cooler or lid of the cooler and that has retractable wheels that retract into the body when the cooler is stationary and released by a spring mechanism to extend the wheels for rolling the cooler.Type: GrantFiled: April 16, 2018Date of Patent: December 21, 2021Inventor: David McGowan
-
Patent number: 11198699Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 31, 2020Date of Patent: December 14, 2021Assignee: Aligos Therapeutics, Inc.Inventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Jerome Deval, Leonid Beigelman, David McGowan, Yannick Debing
-
Publication number: 20210355112Abstract: Disclosed herein are compounds of Formula I: TL-La-CE-HD??(I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IIa, IIb, IIIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds.Type: ApplicationFiled: May 25, 2021Publication date: November 18, 2021Applicant: ALIGOS THERAPEUTICS, INC.Inventors: Koen Vandyck, Pierre Jean-Marie Bernard RABOISSON, David McGowan, Jerome Deval
-
Patent number: 11091467Abstract: Disclosed herein are compounds of Formula I: TL-La-CE-HD??(I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IIa, IIb, IIIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds.Type: GrantFiled: May 7, 2020Date of Patent: August 17, 2021Assignee: Aligos Therapeutics, Inc.Inventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, David McGowan, Jerome Deval
-
Publication number: 20210023082Abstract: This invention relates to pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections such as HCV or HBV.Type: ApplicationFiled: September 4, 2020Publication date: January 28, 2021Inventors: David McGowan, Pierre Jean-Marie Bernard Raboisson, Werner Embrachts, Tim Hugo Maria Jonckers, Stefaan Julien Last, Serge Maria Aloysius Pieters, Jeromir Vlach
-
Publication number: 20200354345Abstract: Disclosed herein are compounds of Formula I: TL-La-CE-HD??(I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IIa, IIb, IIIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds.Type: ApplicationFiled: May 7, 2020Publication date: November 12, 2020Applicant: ALIGOS THERAPEUTICS, INC.Inventors: Koen Vandyck, Pierre Jean-Marie Bernard RABOISSON, David McGowan, Jerome Deval
-
Publication number: 20200317686Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 31, 2020Publication date: October 8, 2020Inventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Jerome Deval, Leonid Beigelman, David McGowan, Yannick Debing
-
Patent number: 10780089Abstract: This invention relates to pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections such as HCV or HBV.Type: GrantFiled: August 2, 2019Date of Patent: September 22, 2020Assignee: JANSSEN SCIENCES IRELAND UCInventors: David McGowan, Pierre Jean-Marie Bernard Raboisson, Werner Embrechts, Tim Hugo Maria Jonckers, Stefaan Julien Last, Serge Maria Aloysius Pieters, Jaromir Vlach
-
Publication number: 20200061059Abstract: This invention relates to pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections such as HCV or HBV.Type: ApplicationFiled: August 2, 2019Publication date: February 27, 2020Inventors: David McGowan, Pierre Jean-Marie Bernard Raboisson, Werner Embrechts, Tim Hugo Maria Jonckers, Stefaan Julien Last, Serge Maria Aloysius Pieters, Jaromir Vlach
-
Patent number: 10420767Abstract: This invention relates to pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections such as HCV or HBV.Type: GrantFiled: January 10, 2018Date of Patent: September 24, 2019Assignee: Janssen Sciences Ireland UCInventors: David McGowan, Pierre Jean-Marie Bernard Raboisson, Werner Embrechts, Tim Hugo Maria Jonckers, Stefaan Julien Last, Serge Maria Aloysius Pieters, Jaromir Vlach
